blood withdrawal
blood withdrawal is a genetic therapy with 41 clinical trials. Currently 14 active trials ongoing. Historical success rate of 94.1%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
88.9%
16 of 18 finished
11.1%
2 ended early
14
trials recruiting
41
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping
Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers
Genetic Variants of Annexin A2 and Cryptogenic Stroke
Clinical Trials (41)
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping
Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers
Genetic Variants of Annexin A2 and Cryptogenic Stroke
Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic
Neuroinflammation in FTLD
Artificial Intelligence Models to Predict Clinically Relevant Cardiovascular Outcomes
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
Blood Extracellular Vesicles as Predictive Recovery Biomarker After Stroke and Brain Injury
Extracellular Vesicles as Stroke Biomarkers
Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.
The Microbiome in (Non-) Obese Pregnancy and Pregnancy Outcomes
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID
Bleeding In Thrombocytopenia Explained
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 41